Анализ результатов биопсий предстательной железы, выполненных с 10-летним интервалом

prostate cancer, biopsy, PSA

1. Romics I., Fischer G., Bе ’ ly M. et al. Experience with prostate cancer screening. Magy Urol (Hung Urol in Hungarian) 1998;10:428—32.

2. Oliver S.E., Gunnel D., Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000;355:1788—9.

3. Brawer M.K., Chetner M.P., Beatle J. et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841—5.

4. Benson M.C., Whang I.S., Olsson C.A. et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817—21.

5. Romics I. Prognostic factors of prostate cancer. Magy Urol (Hung Urol in Hungarian) 1998;10:103—9.

6. Romics I. The technique of ultrasound guided prostate biopsy. World J Urol 2004;22:353—6.

7. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273—9.

8. Neal D.E., Clejan S., Sarma D. et al. Prostate specific antigen and prostatitis. Prostate 1992;20:105—11.

9. Pajor L., Kisbenedek L., Romics I. Therapy of prostate cancer. Magy Urol (Hung Urol in Hungarian) 2003;15:46—55.

10. Stamey T.A., Caldwell M., McNeal J.E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297—301.

11. De Koning H.J., Auvinen A., Berenguer Sanchez A. et al. Large-scale randomized prostatae cancer screening trials: program performances in the european randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237—44.